argenex (NASDAQ:ARGX) Price Target Cut to $1,247.00 by Analysts at Wells Fargo & Company

argenex (NASDAQ:ARGX) had its target price lowered by Wells Fargo & Company from $1,317.00 to $1,247.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other research firms have also issued reports on ARGX. Evercore boosted their price target on shares of argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Citigroup cut their price target on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Wedbush reissued an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research report on Wednesday, January 14th. Wall Street Zen downgraded shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Finally, Royal Bank Of Canada boosted their target price on shares of argenex from $860.00 to $925.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,001.17.

argenex Stock Up 0.9%

Shares of ARGX traded up $6.58 during mid-day trading on Friday, reaching $778.11. 218,086 shares of the stock traded hands, compared to its average volume of 388,582. The firm has a market cap of $48.15 billion, a price-to-earnings ratio of 33.39, a P/E/G ratio of 0.71 and a beta of 0.37. argenex has a 12-month low of $510.05 and a 12-month high of $934.62. The stock has a fifty day simple moving average of $828.13 and a 200 day simple moving average of $809.87.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 26th. The company reported $8.02 EPS for the quarter, topping analysts’ consensus estimates of $6.05 by $1.97. argenex had a net margin of 41.58% and a return on equity of 29.78%. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. On average, equities research analysts expect that argenex will post 3.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On argenex

Hedge funds and other institutional investors have recently made changes to their positions in the business. Abound Wealth Management raised its position in argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after purchasing an additional 32 shares in the last quarter. Sound Income Strategies LLC acquired a new stake in argenex during the fourth quarter valued at approximately $28,000. Ameriflex Group Inc. bought a new stake in shares of argenex in the 3rd quarter valued at approximately $32,000. Aventura Private Wealth LLC acquired a new position in shares of argenex in the 4th quarter worth approximately $38,000. Finally, Sunbelt Securities Inc. bought a new position in shares of argenex during the 3rd quarter worth approximately $36,000. 60.32% of the stock is owned by institutional investors.

argenex News Roundup

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Q4 results beat expectations — argenx reported $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B est; strong margins and ROE underline profitability and drove investor optimism. Listen to Conference Call / Press Release
• Positive Sentiment: Positive Phase 3 ADAPT OCULUS topline for VYVGART in ocular MG — the study met its primary endpoint (p=0.012); results support a planned sBLA to expand the label, which materially increases commercial upside. argenx Announces Positive Topline Results
• Positive Sentiment: Robust FY2025 sales and growth — company reported $1.3B Q4 and $4.2B full-year product net sales (≈90% YoY growth), supporting revenue trajectory and valuation narratives. Full-Year 2025 Financial Results
• Positive Sentiment: Analyst price-target upgrades — Citizens JMP raised its PT to $944 and kept a market‑outperform view, signaling ~20%+ upside and reinforcing buy-side momentum. Benzinga
• Positive Sentiment: HC Wainwright also raised its PT to $940 and maintains a buy rating, adding further sell‑side support for the rally. Benzinga
• Neutral Sentiment: Robert W. Baird nudged its PT to $867 but kept a “neutral” rating — a modest signal versus the more bullish raises, so impact is mixed. Benzinga
• Neutral Sentiment: Company provided standard earnings materials (press release, slide deck, call transcript) for the quarter — useful for modeling but not new directional news. View Press Release / Slide Deck
• Neutral Sentiment: Short-interest data in the feed shows zero/NaN entries (likely reporting noise) and indicates no clear short-pressure signal. Benzinga Short Interest
• Negative Sentiment: Guggenheim trimmed its PT from $1,160 to $1,120 — still a large implied upside and a buy rating, but the downward revision may temper some momentum among more price‑sensitive investors. Benzinga

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.